[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Waisberg J, André EA, Franco MI, Abucham-Neto JZ, Wickbold D, Goffi FS: Curative resection plus adjuvant chemotherapy for early stage primary gastric non-Hodgkin's lymphoma: a retrospective study with emphasis on prognostic factors and treatment outcome. Arq Gastroenterol; 2006 Jan-Mar;43(1):30-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection plus adjuvant chemotherapy for early stage primary gastric non-Hodgkin's lymphoma: a retrospective study with emphasis on prognostic factors and treatment outcome.
  • BACKGROUND: There is controversy regarding the optimal therapy for primary non-Hodgkin gastric lymphoma with some authors defending surgical extirpation either alone or in association with radiotherapy and or chemotherapy, especially in relation to the earlier stages of the disease.
  • AIM: To analyze the clinical-pathological features and the results of management approaches for patients with primary early-stage non-Hodgkin's lymphoma of the stomach operated in Surgical Gastroenterology Department, "Hospital do Servidor Público Estadual", São Paulo, SP, Brazil.
  • The literature is reviewed to highlight the aspects of diagnosis, prognostic factors and role of the various treatment regimens.
  • METHOD: Sixteen patients with primary early-stage gastric lymphoma underwent curative surgical treatment.
  • The variables analyzed were age, sex, location, size, type of surgery, number of lesions, depth of invasion, histological type in accordance with Kiel's classification, involvement of lymph nodes, Ann Arbor stage classification modified by Musshoff and Schmidt-Vollmer, histological grade, margins, adjuvant therapy, clinical course and survival.
  • Primary gastric lymphoma classified histologically as low or high grade was presented by 10 (62.5%) and 6 (37.5%) patients, respectively.
  • The most frequent histological types were the lymphoplasmocytic cytoid (4/25.0%) and centroblastic (4/25.0%).
  • Ten patients (62.5%) received adjuvant treatment (chemotherapy and/or radiotherapy).
  • %) had received adjuvant therapy.
  • CONCLUSIONS: Among the patients with primary early-stage gastric lymphoma (IE and IIE1), the gastric resection enabled an accurate clinicopathological staging, in addition to obtaining sufficient material for histopathological study and extirpation of the lesion.
  • Furthermore, for patients with stage IE disease, the gastric resection combined with adjuvant therapy was associated with a greater than 5-year survival.
  • Until prospective randomized studies are realized in order to evaluate the real efficacy of the different types of treatment for primary early-stage gastric lymphoma, management approaches should be individually tailored.
  • [MeSH-major] Gastrectomy / methods. Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699615.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 37
  •  go-up   go-down


2. Bouhnik Y, Etienney I, Nemeth J, Thevenot T, Lavergne-Slove A, Matuchansky C: Very late onset small intestinal B cell lymphoma associated with primary intestinal lymphangiectasia and diffuse cutaneous warts. Gut; 2000 Aug;47(2):296-300
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late onset small intestinal B cell lymphoma associated with primary intestinal lymphangiectasia and diffuse cutaneous warts.
  • As only a handful of lymphoma cases have been reported in conjunction with primary intestinal lymphangiectasia, it is not yet clear if this association is merely fortuitous or related to primary intestinal lymphangiectasia induced immune deficiency.
  • We report on two female patients, 50 and 58 years old, who developed small intestinal high grade B cell lymphoma a long time (45 and 40 years, respectively) after the initial clinical manifestations of primary intestinal lymphangiectasia.
  • One had a large ulcerated tumour of the proximal ileum and the other diffuse ileal infiltration.
  • In both, histological examination showed centroblastic high grade B cell lymphoma associated with duodenojejuno-ileal mucosal and submucosal lymphangiectasia.
  • They were subsequently successfully treated with surgery and postoperative chemotherapy (AVmCP: adriamycin, cyclophosphamide, Vm26, and prednisolone), and chemotherapy alone (PACOB: adriamycin, cyclophosphamide, vincristine, bleomycine, and prednisolone), respectively.
  • A three year follow up in both cases showed persistent diffuse lymphangiectasia without evidence of lymphoma.
  • The present findings support the hypothesis that primary intestinal lymphangiectasia is associated with lymphoma development.
  • [MeSH-major] Intestinal Neoplasms / etiology. Lymphangiectasis, Intestinal / complications. Lymphoma, B-Cell / etiology. Lymphoma, Non-Hodgkin / etiology. Skin Diseases / etiology. Warts / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphangiectasis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10896925.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] ENGLAND
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC1728014
  •  go-up   go-down


3. Matković S, Jelić S, Manojlović N, Milanović N: Non-Hodgkin's lymphomas with primary localization in large bowel and rectum. Med Sci Monit; 2000 Jan-Feb;6(1):68-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with primary localization in large bowel and rectum.
  • From 1989, at the Department of Medical Oncology of the Institute for Oncology and Radiology in Belgrade, seven patients with primary NHL of large bowel and rectum have been observed and treated, 3 males and 4 females.
  • In 3 patients an urgent laparotomy without previous diagnostic procedures was performed, while 4 patients had laparotomy only after radiographic and endoscopic diagnosis of a tumor.
  • Five patients had lymphoma localized in cecoascedental part of colon (2 centroblastic, 1 lymphoplasmocytic, 1 Burkitt and 1 Burkitt's like), 1 patient had it in the transversal part of colon (centroblastic), and one in the rectum (diffuse centrocytic).
  • Out of 5 patients with localization within cecum or ascendent part of colon, in 2 cases with Burkitt/Burkitt-like histology retroperitoneal lymphadenopathy were found, one female had NHL central propagation, and the other one lymphoma generalization.
  • Both patients had early death from lymphoma.
  • The remaining three patients following chemotherapy with the ProMACE regimen (as they too had a post laparotomy stage II disease) achieved a complete response lasting for 36+, 41+ and 66+ months.
  • A long disease free survival can be obtained in these patients either with surgery only or surgery + chemotherapy, depending on disease stage and possibly initial topographic localization.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208286.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


Advertisement
4. Kath R, Blumenstengel K, Fricke HJ, Peters HD, Höffken K: [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]]. Dtsch Med Wochenschr; 2001 Feb 23;126(8):198-202
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].
  • [Transliterated title] Bendamustin, Vincristin, Prednisolon (BOP) in der Therapie von fortgeschrittenen niedrig malignen Non-Hodgkin-Lymphomen.
  • BACKGROUND AND OBJECTIVE: Low grade non-Hodgkin lymphomas (l-NHL) are rarely showing complete or sustained remissions to conventional chemotherapy.
  • Thus, many therapeutic strategies try to improve the remission rates and outcome in relapsed and refractory l-NHL.
  • Bendamustine (B) is a non-cross resistant alkylating agent shown to be highly effective in lymphoproliferative and other malignant diseases.
  • PATIENTS AND METHODS: 22 patients (median age 61.5 years, range 39-77 years) with relapsed or refractory low grade NHL: immunocytoma (IC) n = 11, centroblastic-centrocytic (CB-CC) n = 6, centrocytic (CC) n = 2, others n = 3, were treated with BOP as follows: patients up to 75 years: 60 mg/m2 B for 5 days; patients over 75 years: 50 mg/m2 B for 5 days.
  • Prior to BOP patients were pretreated with 1-4 chemotherapy protocols.
  • In most patients BOP was followed by a maintenance therapy (IFN-alpha n = 11, chlorambucil n = 4, etoposide n = 2).
  • CONCLUSION: Salvage therapy of refractory and relapsed l-NHL with BOP results in a high objective remission rate.
  • Together with a maintenance therapy most patients achieved a long-term disease-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11256023.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin; COB protocol
  •  go-up   go-down


5. Tomandl J, Palyza V, Tallová J, Drbal J: Time course of urinary neopterin in a non-Hodgkin's lymphoma patient during chemotherapy and radiotherapy. J Exp Clin Cancer Res; 2004 Mar;23(1):157-61
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time course of urinary neopterin in a non-Hodgkin's lymphoma patient during chemotherapy and radiotherapy.
  • The objective of this study was to follow urinary neopterin in a patient affected by non-Hodgkin's lymphoma during the three months treatment from the onset of the disease.
  • In the study a patient affected by non-Hodgkin's lymphoma in Stage IV (centrocyto-centroblastic type) was enrolled.
  • He was treated with combined chemotherapy and local radiotherapy.
  • The time course of urinary neopterin levels ranged from 110 to 524 micromol x mol(-1) creatinine (mean 261, SD 67.5 micromol x mol(-1) creatinine).
  • Longitudinal analysis showed a relatively big variance of urinary neopterin with a tendency of decrease during the treatment.
  • The significant decrease of urinary neopterin was observed till after the radiotherapy period which followed the chemotherapy period.
  • In conclusions, the response to the therapy was accompanied by a reversal tendency of neopterin excretion to physiological values.
  • This study confirms neopterin as a suitable additional parameter for the control of non-Hodgkin's lymphoma therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, Non-Hodgkin / urine. Neopterin / urine
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromatography, High Pressure Liquid. Combined Modality Therapy. Creatinine / urine. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Time Factors. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15149166.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 670-65-5 / Neopterin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; AYI8EX34EU / Creatinine; VAP-cyclo protocol
  •  go-up   go-down


6. Ribrag V, Bibeau F, El Weshi A, Frayfer J, Fadel C, Cebotaru C, Laribi K, Fenaux P: Primary breast lymphoma: a report of 20 cases. Br J Haematol; 2001 Nov;115(2):253-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast lymphoma: a report of 20 cases.
  • Limited data are available concerning treatment and outcome of primary lymphoma of the breast (PLB), especially after CHOP (cyclophosphamide, hydroxydoxorubicin, vincristine, prednisone) chemotherapy.
  • All PLB were of B-cell origin: treatment was CHOP or a CHOP-like regimen in all patients.
  • Two patients had progressive disease on therapy.
  • The two patients who achieved partial remission also had progression in the CNS, 4 and 8 months after the end of CHOP chemotherapy.
  • Of the 16 centroblastic diffuse large B-cell lymphoma (DLCL), three had CNS disease at relapse.
  • Thirteen of the initial 20 patients are alive in CR, six patients have died as a result of their lymphoma and one of unrelated disease.
  • In conclusion, we observed a high incidence of CNS relapse in this group of localized extranodal lymphoma, strongly suggesting that CNS prophylaxis should be associated with systemic chemotherapy in localized PLB.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Prednisone / administration & dosage. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Teniposide / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11703318.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 957E6438QA / Teniposide; VB0R961HZT / Prednisone; CHOP protocol; CHVP protocol
  •  go-up   go-down


7. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A, BFM Group: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol; 2005 Oct;131(1):39-49
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence.
  • We analysed the impact of age and gender on biology and outcome of 2084 patients diagnosed with non-Hodgkin lymphoma (NHL) between October 1986 and December 2002 and treated according to the Berlin-Frankfurt-Münster (BFM) multicentre protocols NHL-BFM-86, -90 and -95.
  • Median age at diagnosis was 8.0 years for 97 precursor B-lymphoblastic lymphoma (pB-LBL) patients, 8.8 years for 335 T-lymphoblastic lymphoma (T-LBL) patients, 8.4 years for 1004 Burkitt's lymphoma/leukaemia (BL/B-AL) patients, 11.4 years for 173 diffuse large B-cell lymphoma (centroblastic subtype) (DLBCL-CB) patients, 13.2 years for 40 primary mediastinal large B-cell lymphoma (PMLBL) patients and 10.8 years for 215 anaplastic large-cell lymphoma (ALCL) patients (P < 0.00001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy


8. Licata A, Pietrosi G, Rizzo A, Pasta L, Pagliaro L: Disseminated non-Hodgkin's lymphoma and chronic hepatitis C: a case report. Ann Ital Med Int; 2003 Oct-Dec;18(4):246-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated non-Hodgkin's lymphoma and chronic hepatitis C: a case report.
  • Hepatitis C virus (HCV) infection is occasionally associated to B-cell type non-Hodgkin's lymphoma.
  • Evidence showing a possible etiological link between HCV and lymphoma has been reported from areas of high HCV prevalence.
  • We describe the case of a 68-year-old woman with B-cell non-Hodgkin's lymphoma mainly involving the skin.
  • Typical manifestations of disease were cutaneous nodules, red-violet in color, scattered on the entire body and adherent to the subcutaneous tissue.
  • A 3-cm nodule excised from the leg was found at histology to consist of centroblastic-like B cells, which stained positively for CD45, CD20 and CD79a.
  • Although the patient was treated with different chemotherapy schedules, she died 1 year later with a diagnosis of disseminated lymphoma.
  • Our report suggests that HCV, a trigger for clonal B-cell proliferation, predisposing to immunological disorders, such as mixed cryoglobulinemia and B-cell malignancies, may also account for the "rare" extranodal high-grade non-Hodgkin's lymphoma.
  • Further observations suggest that treating HCV infection with antiviral therapy could help to prevent the development of B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Hepatitis C, Chronic / complications. Lymphoma, Non-Hodgkin / complications

  • Genetic Alliance. consumer health - Hepatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14971713.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. de Camargo OP, dos Santos Machado TM, Croci AT, de Oliveira CR, Giannotti MA, Baptista AM, Caiero MT, Alves VA, Matsumoto LA: Primary bone lymphoma in 24 patients treated between 1955 and 1999. Clin Orthop Relat Res; 2002 Apr;(397):271-80
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone lymphoma in 24 patients treated between 1955 and 1999.
  • The authors present their experience in the treatment of 24 patients with primary bone lymphoma.
  • Seventeen patients had intermediate-grade lymphomas (Working Formulation), nine patients had centroblastic subtype (Kiel), and 22 patients had B immunophenotype.
  • Nine patients had combined treatment with chemotherapy and radiation therapy, and nine patients had chemotherapy alone.
  • Only one patient had radiation therapy and two patients had no treatment.
  • The results of the current study showed that patients with primary bone lymphoma have a good prognosis when they are treated with chemotherapy, regardless of whether radiation therapy was given.
  • [MeSH-major] Bone Neoplasms / therapy. Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11953618.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, Fournel-Fleury C: Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J; 2004 Mar;167(2):158-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy.
  • The aim of this study was to determine the response of different morphological subtypes of canine lymphoma to a standardized therapeutic protocol.
  • Diagnosis of lymphoma was based on cytohistological analysis and immunophenotyping with antibodies against CD3 and CD79a of an enlarged lymph node or an extranodal mass.
  • Fifty-seven cases were classified according to the updated Kiel classification adapted to the canine species, into 24 B-cell lymphomas (20 centroblastic polymorphic and four Burkitt-type subtypes), and 33 T-cell lymphomas (10 pleomorphic mixed, 10 lymphoblastic, eight unclassifiable high grade plasmacytoid, and five small clear-cell subtypes).
  • All dogs were clinically staged at diagnosis.
  • First remission duration and overall survival time were evaluated.
  • Although the T-cell phenotype was associated, on the whole, with a poor prognosis, as previously reported in veterinary and human medicine, the study showed significant prognostic differences between the B- and the T-cell subtypes of canine lymphoma and suggests that clinico-morphological characterization of the disease is justified in dogs, as in humans.
  • [MeSH-major] Dog Diseases / classification. Dog Diseases / epidemiology. Lymphoma / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dogs. Female. France / epidemiology. Immunophenotyping / veterinary. Male. Prognosis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet J. 2004 Mar;167(2):125-6 [14975385.001]
  • (PMID = 14975390.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Gosev I, Sirić F, Gasparović H, Ugljen R, Nola M, Jelić I: Surgical treatment of a primary cardiac lymphoma presenting with tamponade physiology. J Card Surg; 2006 Jul-Aug;21(4):414-6
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of a primary cardiac lymphoma presenting with tamponade physiology.
  • Pathohistological diagnosis showed diffuse large B-cell lymphoma of centroblastic subtype.
  • Chemotherapy remains the standard treatment of PCL, with surgery reserved for relieving life-threatening complications of the neoplasm.
  • [MeSH-major] Cardiac Surgical Procedures. Cardiac Tamponade / physiopathology. Heart Neoplasms / diagnosis. Heart Neoplasms / surgery. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery
  • [MeSH-minor] Aged. Cardiopulmonary Bypass. Diagnosis, Differential. Echocardiography. Heart Atria / pathology. Heart Atria / ultrasonography. Humans. Immunocompromised Host. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16846425.001).
  • [ISSN] 0886-0440
  • [Journal-full-title] Journal of cardiac surgery
  • [ISO-abbreviation] J Card Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Simonitsch-Klupp I, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, Weltermann A, Greinix HT, Skrabs C, Dittrich C, Lutz D, Pötter R, Mannhalter C, Lechner K, Chott A, Jaeger U: Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia; 2004 Jan;18(1):146-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
  • To define reproducible criteria for subgroups of diffuse large B-cell lymphomas (DLBCL), including lymphomas with plasmablastic/plasmacytoid features (PB/PC-Fs), we investigated 66 DLBCL; the samples were categorized as either centroblastic (CB), immunoblastic (IB) or PB/PC-F applying standardized morphologic criteria.
  • Most PB/PC-F were CD20+, cIgM+, MUM-1+, CD138+/-, bcl-6-, corresponding to an activated B-cell phenotype.
  • Immunoglobulin-V(H) gene mutation analysis was consistent with a germinal or postgerminal center-cell origin.
  • Importantly, PB/PC-F were resistant to standard chemotherapy (complete remission rate 47%, relapse rate 71%) and even autologous stem-cell transplantation.
  • Our data indicate a strong association of plasmablastic/plasmacytoid morphology with TP53 deletions, poor response to chemotherapy and short survival.
  • [MeSH-major] Genes, p53 / genetics. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers / analysis. Female. Follow-Up Studies. Genes, Immunoglobulin. Germinal Center / immunology. Herpesvirus 4, Human / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Lymphoma, Large-Cell, Immunoblastic / classification. Lymphoma, Large-Cell, Immunoblastic / mortality. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Prognosis. RNA, Viral / genetics. Sequence Deletion. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14603341.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / RNA, Viral
  •  go-up   go-down


13. Krieger G, Kreysing E, Kneba M: [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas]. Onkologie; 2001 Feb;24 Suppl 1:49-58
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas].
  • [Transliterated title] Langzeitergebnisse mit MACOP-B und Strahlentherapie bei aggressiven Non-Hodgkin-Lymphomen.
  • BACKGROUND: Long-term results are needed to evaluate chemotherapy regimens and prognostic factors in non-Hodgkin's lymphomas (NHL).
  • PATIENTS AND METHODS: Between 1985 and 1991, 71 patients with aggressive NHL were treated in a single institution with MACOP-B and adjuvant radiotherapy as first-line therapy.
  • The Kiel classification combined with the International Prognostic Index (IPI) identified diffuse large B-cell and anaplastic large T-cell lymphomas with IPI 0-2 as subgroups with very favorable prognosis after MACOP-B (OS 84% and 80% at 10 years).
  • Late relapses (>2 years after therapy) did occur in these patients but had a good prognosis after second remission.
  • Risk factors for therapy-related death were age and pulmonary toxicity.
  • Most patients suffered from chemotherapy-associated mucositis.
  • CONCLUSIONS: MACOP-B in combination with adjuvant radiotherapy is highly effective in diffuse large B-cell or anaplastic large T-cell-lymphomas with IPI 0-2.
  • Patients with IPI >2 or with centrocytic or secondary centroblastic B-cell or non-anaplastic T-cell lymphomas need more intensive therapy or novel approaches.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441311.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MACOP-B protocol
  •  go-up   go-down


14. Gholam D, Bibeau F, El Weshi A, Bosq J, Ribrag V: Primary breast lymphoma. Leuk Lymphoma; 2003 Jul;44(7):1173-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast lymphoma.
  • Primary breast lymphoma (PBL) is a rare form of localized extranodal lymphoma.
  • Few reports are available in the literature concerning its treatment and outcome.
  • Of the 34 cases of PBL seen at our institution over a 25-year period, 20 consecutive cases were treated with CHOP or CHOP-like chemotherapy regimen and had adequate biopsy specimens for histological review.
  • All these 20 PBL were of B-cell origin including one case of Burkitt lymphoma, and 2 cases of low-grade histologic type.
  • Two patients had progressive disease while on therapy.
  • Median time to relapse from diagnosis was 23 months (range, 3-41 months).
  • The two patients who achieved a PR after chemotherapy also had disease progression to the CNS, 4 and 8 months after the end of CHOP chemotherapy.
  • Of the 16 centroblastic diffuse large B-cell lymphoma (DLCL), 3 had CNS disease at relapse.
  • Three (15%) of our study patients developed a controlateral breast relapse.
  • Twelve of the initial 20 patients were alive, including 11 with a persistent CR, 6 patients died of their lymphoma and 2 of unrelated diseases.
  • In conclusion, we observed a high incidence of CNS relapse in this group of localized extranodal lymphoma, strongly suggesting that CNS prophylaxis should be associated with systemic chemotherapy in localized PLB.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Prednisone / therapeutic use. Prognosis. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12916870.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 36
  •  go-up   go-down


15. Li D, Mi C, Zhao Y, Wang YL, Ma Y, Li YY, Xiang MH: [Primary diffuse large B-cell lymphoma of testis: a clinicopathologic study of 14 cases]. Zhonghua Bing Li Xue Za Zhi; 2007 Jul;36(7):461-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of testis: a clinicopathologic study of 14 cases].
  • OBJECTIVE: To study the clinicopathologic features, immunohistochemical findings and prognosis of primary diffuse large B-cell lymphoma (DLBCL) of testis.
  • Histologically, the lymphoma cells of all cases showed a centroblastic appearance.
  • One case belonged to the germinal center B cell-like subtype on immunohistochemical study, while the remaining 13 cases were classified as non-germinal center B cell-like subtype.
  • CONCLUSIONS: Most cases with primary DLBCL of testis were of peripheral activated B-cell origin.
  • Accurate pathologic diagnosis relies on detailed histologic examination and immunohistochemical study.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Germinoma / drug therapy. Germinoma / metabolism. Germinoma / pathology. Germinoma / surgery. Humans. Male. Middle Aged. Neprilysin / metabolism. Orchiectomy. Prednisone / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Retrospective Studies. Seminoma / pathology. Survival Rate. Tumor Suppressor Protein p53 / metabolism. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845759.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


16. Sipsas NV, Kontos A, Panayiotakopoulos GD, Androulaki A, Zormpala A, Balafouta ME, Dounis E, Tsavaris N, Kordossis T: Extranodal non-Hodgkin lymphoma presenting as a soft tissue mass in the proximal femur in a HIV(+) patient. Leuk Lymphoma; 2002 Dec;43(12):2405-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal non-Hodgkin lymphoma presenting as a soft tissue mass in the proximal femur in a HIV(+) patient.
  • Primary soft tissue non-Hodgkin lymphomas (NHL) are very rare especially among HIV-1 infected patients.
  • The clinical and laboratory investigation revealed a high grade centroblastic B-cell lymphoma of soft tissue.
  • The patient was treated by surgical resection of the tumor, chemotherapy and local radiotherapy with no serious side effects.
  • After 36 mdnths of follow up he is in excellent clinical condition, with his lymphoma in complete remission.
  • [MeSH-major] Bone Neoplasms / pathology. Femur / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Remission Induction


17. Eich HT, Heimann M, Stützer H, Kriz J, Reiser M, Müller RP: Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy. Strahlenther Onkol; 2009 May;185(5):288-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy.
  • PURPOSE: Retrospective analysis of therapy results in patients with stage I-II and limited stage III nodal low-grade non-Hodgkin's lymphoma (NHL).
  • 50 patients were treated with radiotherapy alone (EF [extended field]: n = 35, IF/REG [involved field/regional field]: n = 9, TNI/TLI [total nodal/total lymphatic]: n = 6), 15 patients additionally received chemotherapy.
  • 58 patients presented with centroblastic-centrocytic or follicular lymphomas, seven patients had centrocytic lymphomas.
  • Apart from overall and relapse-free survival, relapse patterns were examined and the impacts of patient characteristics and therapy modalities were analyzed.
  • Overall survival was favorably influenced by low patient age (p = 0.037), centroblastic-centrocytic/follicular histology (p = 0.006), and early disease stage (p = 0.045).
  • Favorable prognostic factors for relapse-free survival were low patient age (p = 0.035) and centroblastic-centrocytic/follicular histology (p = 0.001).
  • CONCLUSION: Radiotherapy of early-stage low-grade NHL is a curative therapy option, particularly in younger patients and patients with follicular histology.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / radiotherapy. Radiotherapy, Conformal / mortality
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Germany / epidemiology. Humans. Incidence. Longitudinal Studies. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Assessment / methods. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2007 Jul;183(7):385-91 [17609872.001]
  • [Cites] Strahlenther Onkol. 2001 Nov;177(11):597-603 [11757182.001]
  • [Cites] Cancer. 1995 May 1;75(9):2361-7 [7712449.001]
  • [Cites] Med Oncol. 1994;11(1):19-25 [7921924.001]
  • [Cites] Cancer. 1983 Dec 15;52(12):2300-7 [6416664.001]
  • [Cites] Strahlenther Onkol. 2007 Jan;183(1):17-22 [17225941.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):1-7 [6406037.001]
  • [Cites] Strahlenther Onkol. 1998 Apr;174(4):178-85; discussion 186 [9581177.001]
  • [Cites] Strahlenther Onkol. 2007 Jul;183(7):392-7 [17609873.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):167-71 [8532901.001]
  • [Cites] Strahlenther Onkol. 1992 Feb;168(2):66-72 [1542848.001]
  • [Cites] Strahlenther Onkol. 2003 Oct;179(10):694-701 [14566478.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1596-602 [3756784.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Mar;14(3):417-24 [2449414.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):928-34 [16243446.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Feb;6(2):125-34 [6993438.001]
  • [Cites] Br J Cancer. 1994 Jun;69(6):1088-93 [8198975.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):647-52 [17072522.001]
  • [Cites] Strahlenther Onkol. 2007 Oct;183(10):545-51 [17896085.001]
  • [Cites] Radiother Oncol. 1988 Oct;13(2):91-8 [3059400.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):470-9 [8814695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):563-8 [10348285.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2342-50 [8453557.001]
  • [Cites] Clin Radiol. 1988 May;39(3):287-90 [3396280.001]
  • [Cites] Strahlenther Onkol. 2003 Dec;179(12):840-6 [14652673.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):3-15 [11163492.001]
  • (PMID = 19440667.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Zhao XF, Young KH, Frank D, Goradia A, Glotzbecker MP, Pan W, Kersun LS, Leahey A, Dormans JP, Choi JK: Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases. Am J Clin Pathol; 2007 Jan;127(1):47-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases.
  • Most primary bone lymphomas (PBLs) are diffuse large B-cell lymphomas (DLBCLs).
  • All were successfully treated with chemotherapy with or without radiotherapy (0.5- to 24-year followup).
  • Biopsy revealed that the lymphomas were paratrabecular or diffuse and were medium- to large-sized with round to irregular nuclei, dispersed chromatin, indistinct to small nucleoli, and abundant cytoplasm.
  • Typical centroblastic morphologic features with nucleoli were rare, multilobated nuclei were uncommon, and CD10 negativity did not predict poor prognosis, unlike in the adult PBL-DLBCL.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145622.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


19. Morel P, Souleau B, Morschhauser F, Duhamel A, Dombret H, Tilly H, Reyes F, Brière J, Coiffier B, Celigny PS, Lepage E, Brousse N, GELA (Groupe d'Etude des Lymphomes de l'Adulte): Assessing the Cox model assumption as a statistical tool for classifying lymphomas. Hematol J; 2001;2(5):341-51
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Using log-rank test, we compared event-free survival (EFS), and the survival of 64 patients with mantle cell lymphoma (MCL), 525 patients with follicular lymphoma, and 1136 patients with diffuse centroblastic lymphoma (CB).
  • RESULTS: Although EFS and survival of MCL were significantly shorter than those of follicular lymphoma, checking the validity of the proportional hazards assumption shows that the distribution of rates of events and deaths over time did not differ in MCL and follicular lymphoma.
  • In contrast, the ratios of hazards (events and deaths rates) did not remain constant over time in MCL and CB, because of a decrease in late events and deaths rates in the latter histological type.
  • CONCLUSION: Checking the validity of the Cox model hypothesis might be a useful tool for assessing long-term cure rate in seldom lymphoma subtypes.
  • Despite a short overall survival, MCL should not be considered to be an aggressive lymphoma, in which available chemotherapy may cure a subset of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11920270.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


20. Sturm A, Noppeney R, Reimer J, Ross B, Baumgart D, Sundermann T, Sadony V, Gerken G: [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection]. Dtsch Med Wochenschr; 2001 Mar 30;126(13):364-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS and non-Hodgkin's lymphoma: initial cardiac manifestations of highly malignant B-cell lymphoma 18 years after HIV infection].
  • [Transliterated title] AIDS und Non-Hodgkin Lymphome--kardiale Erstmanifestation eines hochmalignen B-Zellymphoms nach 18 Jahren HIV-Infektion.
  • HISTORY AND FINDINGS: A 35-year-old man who, as a result of intravenous drug abuse, had become infected with HIV 18 years previously, was admitted with signs of right-heart failure.
  • DIAGNOSIS, TREATMENT AND COURSE: Endocarditis with atrial thrombi and recurrent pulmonary emboli was diagnosed and treated with antibiotics and anticoagulants.
  • Computed tomography of skull, thorax and abdomen did not demonstrate any significantly enlarged lymph nodes.
  • Exploratory thoracotomy revealed an infiltrating highly malignant centroblastic non-Hodgkin's lymphoma (NHL) of almost the entire free wall of the right atrium.
  • After two courses of chemotherapy (CHOP protocol) the size of the tumour had significantly decreased.
  • CONCLUSION: The differential diagnosis of a right atrial tumour can be difficult in patients with HIV or AIDS.
  • Even if the site is atypical and there is no lymphadenopathy, a lymphoma should be considered.
  • In case of doubt a histological diagnosis via an exploratory thoracotomy should be performed.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Echocardiography, Transesophageal. Heart Atria / pathology. Humans. Male. Prednisone / administration & dosage. Substance Abuse, Intravenous / complications. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332231.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, Trümper L, Brugger W, Ostermann H, Atzpodien J, Hallek M, Aulitzky E, Hiddemann W: IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol; 2000 Sep;79(9):493-500
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
  • PURPOSE: The current study was initiated to assess the clinical efficacy and side effects of rituximab in patients with relapsed advanced stage follicular lymphoma.
  • PATIENTS AND METHODS: The study was performed as an open-label non-randomized multicenter phase-II trial and included patients older than 18 years of age with relapsed advanced-stage follicular lymphomas (FL) grades I and II, according to the REAL classification, or with centroblastic/centrocytic (CB/CC lymphomas according to the Kiel classification.
  • The median time between primary diagnosis and study entry was 4.6 years (range 0.9-14.7 years).
  • Twenty grade-III/IV side effects were considered to be related to treatment: lymphocytopenia (3), granalocytopenia (1), thrombocytopenia (2), fever (1), hyperglycermia (1), venous thrombosis (1), syncope (1), plasmatic coagulation disorder (1), shortness of breath (2), photosensitivity (1), cardiac failure (1), chills (1), sepsis (1), tumor lysis (1), anemia (1), and pharyngeal edema (1).
  • Eight patients were not eligible for assessment of response because of non-follicular subtypes of low-grade lymphomas (n =6) or early termination of therapy at the first infusion because of severe side effects (n =2).
  • The median time to treatment progression (TTP) was 201 days (range 64-293 days), with five patients experiencing long-lasting remissions of 214-293 days duration.
  • CONCLUSION: This study confirms the moderate treatment-related toxicity and the high antilymphoma activity of rituximab in patients with relapsed follicular lymphoma.
  • Further studies are needed to determine the role of rituximab in the first-line treatment of these disorders and its combination with conventional chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11043420.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


22. Waisberg J, Bromberg SH, Franco MI, Stephani SM, Zanotto A, de Godoy AC, Goffi FS: The role of surgery in the treatment of primary gastric lymphoma. Int Surg; 2000 Jul-Sep;85(3):219-25
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surgery in the treatment of primary gastric lymphoma.
  • The present retrospective study of 23 patients with primary gastric lymphoma had the objective of determining the role of surgical treatment on survival.
  • All patients were submitted to gastric resection with regional lymph node removal.
  • Nine patients (39.1%) received supplementary treatment (chemotherapy and/or radiotherapy).
  • According to the Kiel classification, the most frequent histological type was the centroblastic (29.1%), and most patients (60.9%) had a low-grade lymphoma.
  • The variables that influenced survival rates were age, advanced stage tumor, and receiving postoperative adjuvant therapy.
  • Analysis of our cases suggests that complete lesion resection along with adjacent lymph nodes, and supplementary postoperative treatment is the best approach for a resectable primary gastric lymphoma.
  • [MeSH-major] Lymphoma / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11324999.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Charousset C, Anract P, Carlioz B, Babinet A, Tomeno B: [Primary bone lymphoma. Retrospective immunohistochemical study of 22 cases]. Rev Chir Orthop Reparatrice Appar Mot; 2002 Sep;88(5):439-48
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary bone lymphoma. Retrospective immunohistochemical study of 22 cases].
  • Results of two treatments, chemotherapy alone versus chemotherapy then radiotherapy, were compared in terms of local control and patient survival.
  • Histology generally described diffuse large centroblastic lymphoid cells, all with B phenotype.
  • Twelve patients were treated with chemotherapy alone and eight with chemotherapy and radiotherapy.
  • One patient was only given palliative treatment with corticosteroids due to major immunodepression.
  • The last patient, a 79-year-old woman, developed a tumor of the femoral neck; at surgery section of the neck removed the entire tumor, but radiotherapy (30 Gy) centered on the femur was nevertheless performed.
  • Mean 5-year Kaplan-Meier survival was 74.41% for the overall series, 83.33% for the chemotherapy group and 82.50% for the chemotherapy-radiotherapy group.
  • DISCUSSION: We were unable to demonstrate any significant difference in survival between the two types of treatment.
  • Our observations suggest that technetium scintigraphy is more sensitive than MRI and more specific for diagnosis.
  • Radiography, together with clinical examination and is indicated to monitor these patients during and after treatment.
  • Based on this series, patients with primary bone lymphoma should be given chemotherapy, either alone or combined with radiotherapy, rather than radiotherapy alone.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / therapy. Immunohistochemistry. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Female. Fractures, Spontaneous / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pain / etiology. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Sex Distribution. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12399708.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Gandemer V, Verkarre V, Quartier P, Brousse N, Blanche S: [Lymphomas in children infected with HIV-1]. Arch Pediatr; 2000 Jul;7(7):738-44
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Lymphomes chez l'enfant infecté par le VIH-1.
  • PURPOSE: To describe the features of lymphoma in human immunodeficiency virus (HIV)-infected children, their treatments and the outcome of patients.
  • RESULTS: We analyzed seven HIV-infected children (four by mother-to-child transmission and three by transfusion) (25 months to 18.5 years old) with lymphoma (one Hodgkin's disease and six non-Hodgkin's lymphomas).
  • Five of six were high grade-B cell non-Hodgkin's lymphoma of large-cell histologies (immunoblastic or centroblastic).
  • Five were extranodular disease and three were metastatic at diagnosis.
  • Five of seven received a multiagent chemotherapy.
  • Treatment for the skin T lymphoma consisted of radiation therapy.
  • Five children were complete responders (with survival three years, 2.5 years, 12, 18 and 18 months) and two died of progression of lymphoma (four and five months later).
  • CONCLUSION: Incidence of lymphoma is increased in HIV-infected children.
  • Anticancer chemotherapy regimens that include aggressive supportive care and concomitant antiretroviral therapy or immunotherapy may yield high survival rates.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. HIV-1. Humans. Immunotherapy. Male. Prognosis. Survival Analysis


25. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, Vaccher E, Carbone A, Tirelli U: Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol; 2003 Nov 1;21(21):3948-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.
  • PURPOSE: To describe the clinical features and outcome of HIV-associated primary effusion lymphoma (PEL) and to compare them with those of the other HIV-associated non-Hodgkin's lymphomas (NHLs).
  • Clinical features and outcome of PEL patients were compared with the features and outcomes of 162 patients belonging to the following histologic subtypes: plasmoblastic lymphoma of oral cavity (PBLOC, n = 11), immunoblastic lymphoma (IBL, n = 76), and centroblastic B-cell lymphoma (CBCL, n = 75).
  • Complete remission was reached in 42% of patients, with a median survival time of 6 months.
  • CONCLUSION: PEL is a rare HIV-associated NHL type occurring as a late manifestation of HIV infection with a poor clinical outcome and a shorter overall survival compared with CBCL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Italy / epidemiology. Male. Medical Records. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage


26. Corti M, Villafañe MF, Cermelj M, Candela M, Pérez Blanco R, Tezanos Pinto M: [Cavum lymphoma in a hemophilic patient with AIDS]. Medicina (B Aires); 2000;60(3):351-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cavum lymphoma in a hemophilic patient with AIDS].
  • [Transliterated title] Linfoma de cavum en un paciente hemofílico con SIDA.
  • Intermediate and highly malignant non-Hodgkin and primary central nervous system lymphomas are marker diseases for AIDS.
  • We present a hemophilic HIV+ patient with non-Hodgkin lymphoma of the cavum.
  • The histologic diagnosis was high-grade, pleomorphic, centroblastic lymphoma.
  • The patient was treated with chemotherapy plus intrathecal chemotherapy and highly active antiretroviral therapy (HAART).
  • One year after diagnosis, the patient is asymptomatic with no evidence of residual tumor, and responding well to HAART.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Hemophilia A / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Nasopharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hemophilia.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11050815.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] ARGENTINA
  •  go-up   go-down


27. Pierach CA: [Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non hodgkin lymphoma]. Dtsch Med Wochenschr; 2000 Aug 4;125(31-32):958-60
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non hodgkin lymphoma].
  • [Transliterated title] Langfristig guter Verlauf unter Misteltherapie bei einem Patienten mit einem zentroblastisch-zentrozytischen Non-Hodgkin-Lymphom.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Lymphoma, Follicular / drug therapy. Mistletoe / therapeutic use. Phytotherapy. Plant Extracts / therapeutic use. Plants, Medicinal
  • [MeSH-minor] Complementary Therapies. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Dtsch Med Wochenschr. 1999 Nov 26;124(47):1414-8 [10605421.001]
  • (PMID = 10967963.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Comment; Letter
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
  •  go-up   go-down






Advertisement